Becky Bish | The Mark Foundation for Cancer Research
Nomura in his lab at UC Berkeley. Photo: Elena Zhukova
Throughout the grim reality of a global pandemic that has disrupted normal life for months, one persistent bright spot has been the robust response of the biomedical research community. The battle to develop vaccines and drugs to fight the SARS-CoV-2 virus and COVID-19, the disease which it causes,...
A colored scanning electron micrograph of a cell of a common type of lung cancer, called non-small cell cancer. A new drug targets the mutated protein that leads to uncontrolled growth. Credit Steve Gschmeissner/Science Source
After 40 years of effort, researchers have finally succeeded in switching off...
The DNA-cutting proteins central to CRISPR-Cas9 and related gene-editing tools originally came from bacteria, but a newfound variety of Cas proteins apparently evolved in viruses that infect bacteria. The new Cas proteins were found in the largest known bacteria-infecting viruses, called bacteriophages, and are the most compact working Cas variants yet discovered — half the size of today’s workhorse, Cas9.
Even the hippest chemist doesn’t know how many potentially world-changing chemistry start-ups are out there. As we at C&EN present our fifth class of 10 Start-Ups to Watch (two companies are founded by UC Berkeley faculty and alum), we can confirm that there are definitely hundreds, and perhaps thousands. That makes the job of picking just 10 a challenge—though an inspiring one. This year’s choices were selected after vigorous debate by our writers and editors. We made our own lists based on our day-to-day reporting and scoured the hundreds of firms nominated by readers and advisers from around the world. We picked winners for their groundbreaking chemistry as well as the importance of the problems they are tackling.
When Chu-Moyer was tapped to head up the research and chemistry groups across Amgen’s three U.S. R&D sites in 2014, she knew she would have to make some changes for the company to succeed in bringing a KRAS inhibitor into clinical trials, along with other novel treatments for cancer, cardiovascular disease and neurological disorders. For one, she needed to improve the collaboration between scientists who had different areas of expertise—and who lived and worked in different zip codes.
In the modern age of pharmacology, some of the newest heroes in the war against human disease are biologists and chemists working in chemical proteomics. Among the leaders in this research is the Novartis-Berkeley Center for Proteomics and Chemistry Technologies (NB-CPACT), a joint venture linking Novartis, a large pharmaceutical company, and the world’s leading public research university. Launched in October 2017, the center is developing new technologies to further the discovery of next-generation therapeutics for cancer and other diseases.
Frontier Medicines has announced the launch of a new startup to actively develop medical treatments for currently "undruggable" diseases. According to the American Cancer Society, approximately 1,762,000 new cancer cases and approximately 607,000 deaths from cancer are expected to occur in the US in 2019.
by Nanticha Lutt | Berkeley College of Natural Resources
UC Berkeley scientists have published a new study in Nature Chemical Biology that investigates how nimbolide, a natural product derived from the neem tree, may function in impairing cancer pathogenicity.
Frontier Medicines has announced the launch of a new startup to actively develop medical treatments for currently "undruggable" diseases. According to the American Cancer Society, approximately 1,762,000 new cancer cases and approximately 607,000 deaths from cancer are expected to occur in the US in 2019.
UC Berkeley scientists have published a new study in Nature Chemical Biology that investigates how nimbolide, a natural product derived from the neem tree, may function in impairing cancer pathogenicity.